3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
2
Colorectal Neoplasms
2
Solid Malignant Tumors
1
Recurrence
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Glioblastoma
1
Carcinoma, Hepatocellular
1
Interventions
Bevacizumab
11
durvalumab
9
atezolizumab
9
Specimen Handling
9
tremelimumab
8
lenvatinib
7
Nivolumab
6
Magnetic Resonance Spectroscopy
5
X-Rays
4
Sorafenib
3
Oxaliplatin
3
Ipilimumab
3
Fluorouracil
3
tislelizumab
2
sapanisertib
2
relatlimab
2
cabozantinib
2
Surgical Procedures, Operative
2
Radiation
2
Leucovorin
2
Immunotherapy
2
Immunoglobulin G
2
Doxorubicin
2
Disulfides
2
Carboplatin
2
ulixertinib
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
trametinib
1
sofosbuvir-velpatasvir drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
regorafenib
×
30 days
×
Clear all
NCT07495579
2026-05-27
REVIVE
Asan Medical Center
Phase 2
Not yet recruiting
146 enrolled